What is VoluMetrix?
VoluMetrix operates at the intersection of advanced biomedical engineering and clinical application. With deep institutional ties to the Vanderbilt University Medical Center and the Mayo Clinic Innovation Exchange, the firm is dedicated to refining its NIVA platform. This technology represents a paradigm shift in how vital signs are captured, moving away from invasive procedures toward seamless, continuous monitoring. The company's current lifecycle stage, supported by this late-stage financing, reflects a transition from foundational research and development toward the rigorous validation required for regulatory approval and eventual commercialization in the United States healthcare market.
How much funding has VoluMetrix raised?
VoluMetrix has raised a total of $308K across 2 funding rounds:
Debt
$150K
Debt
$158K
Debt (2020): $150K with participation from PPP
Debt (2021): $158K led by PPP
Key Investors in VoluMetrix
PPP
Public-Private Partnership
What's next for VoluMetrix?
With the infusion of $158K, VoluMetrix is poised to accelerate its clinical trial roadmap and expand its research initiatives supported by the National Institutes of Health. The strategic focus will likely shift toward optimizing the NIVA platform for broader clinical utility, ensuring that the transition from hospital-based monitoring to home-based care is both scalable and reliable. As the company navigates the complex regulatory landscape, the focus remains on establishing the efficacy of its non-invasive solutions, ultimately aiming to improve patient outcomes through enhanced, real-time physiological data accessibility.
See full VoluMetrix company page
